International Reporting Scale of BCR-ABL1 Fusion Transcript in Chronic Myeloid Leukemia: First Report from IndiaBalasubramanian P. · Chendamarai E. · Markose P. · Fletcher L. · Branford S. · George B. · Mathews V. · Chandy M. · Srivastava A.
aDepartment of Haematology, Christian Medical College, Vellore, India; bSA Pathology and The University of Adelaide, Adelaide, S.A., Australia
Achieving a major molecular response (MMR) is an important predictor of progression-free survival in chronic myeloid leukemia patients treated with imatinib. This requires accurate measurement of BCR-ABL1 transcripts normalized to a control gene, as well as defining a level (BCR-ABL1/control gene ratio) that will correlate with sustained clinical response. To make these measurements comparable between laboratories, an international scale (IS) is necessary. A BCR-ABL1/control gene ratio of 0.10% represents MMR in the IS. In collaboration with an international reference laboratory in Adelaide, S.A., Australia, we have established and validated a lab-specific conversion factor for expressing BCR-ABL1 transcript levels in the IS. In this report, we explain the process and steps involved in obtaining a valid lab-specific conversion factor for expressing BCR-ABL1 transcript levels in the IS.
Prof. Poonkuzhali Balasubramanian, PhD
Department of Haematology
Christian Medical College
Vellore 632004 (India)
Tel. +91 416 228 3476, E-Mail email@example.com
E. Chendamarai and P. Markose contributed equally to this paper.
Received: May 25, 2011
Accepted after revision: October 18, 2011
Published online: January 12, 2012
Number of Print Pages : 8
Number of Figures : 4, Number of Tables : 0, Number of References : 16
Additional supplementary material is available online - Number of Parts : 2
Vol. 127, No. 3, Year 2012 (Cover Date: March 2012)
Journal Editor: Ben-Bassat I. (Qiryat-Ono)
ISSN: 0001-5792 (Print), eISSN: 1421-9662 (Online)
For additional information: http://www.karger.com/AHA